Enzymology & Mechanistic Pharmacology GlaxoSmithKline Pharmaceuticals
GlaxoSmithKline Pharmaceutical Company
Robert A. Copeland, Ph.D. is Vice President, Enzymology & Mechanistic Pharmacology
at GlaxoSmithKline Pharmaceutical Company, where he supports efforts in oncology,
infectious, cardiovascular and urogenital diseases. He is also Adjunct Professor
of Biochemistry and Biophysics and a Fellow of the Eldridge Reeves Johnson Foundation
at the Univ. of Pennsylvania School of Medicine.
He received his doctorate in chemistry from Princeton Univ. and went on to do postdoctoral
studies at the California Institute of Technology. Before joining GSK he held scientific
staff positions at Merck Research Laboratories, DuPont Merck and Bristol-Myers Squibb
and a faculty position at the University of Chicago, Prizker School of Medicine.
research interest is in elucidating the determinants of drug recognition by their
biological targets, and the use of this information in the discovery and design
of new medicines.
He has made significant contributions to drug discovery projects across a wide range
of therapeutic areas, and has received numerous awards for his research accomplishments.
His awards include a Synthex Scholars Award for excellence in cardiovascular research
and an Established Investigatorship from the American Heart Association. Dr. Copeland
over 130 papers and reviews in scientific journals and has authored 4 books in the
areas of protein biochemistry and enzymology. His latest book, Evaluation of Enzyme
Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists
published in March 2005.